A new drug that combines Actos with an angiotensin receptor blocker called TAK-536 has entered into Phase III clinical trials in the United States, Takeda Pharmaceuticals has reported. The drug is designed to control both glucose levels and hypertension in patients with Type 2 diabetes. Approximately 60 percent of patients in the U.S. who have diabetes also have hypertension.
Read moreA newly published study, The Role of Clinical Uncertainty in Treatment Decisions for Diabetic Patients with Uncontrolled Blood Pressure,... Read more »
My last blog discussed transitioning to college with the exciting changes in routine, independence, and lifestyle. The summer also is a... Read more »
The past year was a big one in hypertension. A number of trials were reported at meetings and in the medical literature with great... Read more »
An Italian study has shown that people who have both Migraines and hypertension have a higher probability of cerebrovascular events than... Read more »
There are several hypertension complications that you should be aware of. Hypertension stresses the organs out within the body. The added... Read more »
The blood-pressure drug Rasilez was found to be more effective in treating high blood pressure in diabetics than the standard treatment, Ramipril,... Read more »
A new drug called darusentan has shown promise for treating people with hard-to-treat high blood pressure in a pivotal clinical trial. In the study,... Read more »
Officials with the International Society of Hypertension in Blacks are calling for earlier and more aggressive intervention for the black community,... Read more »
A readers who suffers from pulmonary hypertension asks if a stem cell therapy available in the Dominican Republic could help treat her condition. Dr.... Read more »
This is a study to test the safety and effectiveness of a new device, the Rheos Baroreflex Hypertension System, in people whose high blood pressure... Read more »